Skip to main content
OpenTrials
Completed

NCT Number: NCT01914692

Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection

Gastric cancer radical surgery related complications are common.Somatostatin is a conventional medical therapy for bleeding.This study explore the effect of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node dissection.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Gastric Cancer After D2 Lymph Node Dissection

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • More than eighteen years old
  • Gastric cancer diagnosed by pathological examination
  • Be given informed consent
  • Without diabetes/hyperthyroidism/Damages of functions of heart, liver and kidney/Systemic Infection/immunodeficiency

Exclusion criteria

  • Contraindication of vascular puncture operation
  • Patients who refused to take part in the programe
  • Poor compliance of treatment
  • Malnutrition,BMI<18
  • with pancreatectomy

Treatment and study plan

Somatostatin

Drug

Somatostatin is a kind of traditional medicines ,which is for the treatment of intestinal fistula，upper gastrointestinal hemorrhage.

Primary outcomes

  1. fistula of pancreas

    Time frame: one year

    number of patients

Secondary outcomes

  1. amount of bleeding

    Time frame: six months

    amount of bleeding after the operation

  2. seroperitoneum

    Time frame: six months

    seroperitoneum volum of patients

  3. infection of incisional wound

    Time frame: one year

    number of patients

Other outcomes

  1. postoperative pancreatitis

    Time frame: one year

    number of patients

Sponsors and collaborators

Lead sponsor

First Affiliated Hospital, Sun Yat-Sen University

Other

Registry information

Official study title

Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection -a Prospective Randomized Controlled Study

Important dates

Study start
2013
Primary completion
2013
Study completion
2013
First posted
Aug 2, 2013
Registry last updated
Aug 2, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.